₹33.00 Crores | Listing at NSE | Mon, Mar 16, 2026 - Tue, Mar 24, 2026
Jfl Life Sciences Limited Rights Issue comprises 3.30 Cr equity shares aggregating to ₹33.00 Cr, offered at an issue price of ₹10 per share with a face value of ₹10 per share.
The record date for determining eligible shareholder is Mar 10, 2026, with the Rights Issue being offered in the entitlement ratio of 1 : 1.
The term of payment is defined as following :
The Rights Entitlements are expected to be credited to eligible demat accounts on Mar 30, 2026.
The Rights Issue opens on Mar 16, 2026, and closes on Mar 24, 2026, with renunciation of Rights Entitlements permitted up to Mar 19, 2026.
The deemed date of allotment is Mar 30, 2026, following which the equity shares are expected to be credited to demat accounts on Apr 2, 2026 and listed at the NSE on Apr 7, 2026.
Investors are advised to refer to the Jfl Life Sciences Limited Letter of Offer for detailed information, including risk factors, issue terms, and procedural details.
Record Date
Tue, Mar 10, 2026
Entitlement Ratio
1 : 1
Open Date
Mon, Mar 16, 2026
Close Date
Tue, Mar 24, 2026
| Period Ended | 31 Mar 2025 | 31 Mar 2024 |
|---|---|---|
| Assets | 71.91 | 56.71 |
| Total Income | 82.05 | 47.06 |
| Profit After Tax | 3.30 | 4.16 |
| Amount in ₹ Crore | ||
Incorporated on April 25, 2010, JFL Life Sciences Limited is an Ahmedabad-based pharmaceutical manufacturing company.
The company is engaged in the manufacturing of pharmaceutical formulations such as dry powder injections, tablets and capsules (Beta-Lactam and general), and oral rehydration solutions (ORS). Its manufacturing facilities are located at the GIDC estate in Bavla, Ahmedabad, Gujarat.
JFL Life Sciences supplies its products across India and exports to several international markets including Africa, the Middle East, and CIS countries. The company focuses on quality manufacturing, supported by research and development and modern production facilities to meet global healthcare demand.
The Company proposes to utilise the Net Proceeds from the Issue towards the following objects:
| # | Issue Objects | Est Amt (₹ Cr.) |
|---|---|---|
| 1 | Construction of new manufacturing plant | 9.52 |
| 2 | Installation of Machinery | 5.52 |
| 3 | Working Capital Requirement | 13.45 |
| 4 | General corporate purposes | 3.52 |
| Total | 32.00 |
[Dilip Davda] JLSL is engaged in the pharma/healthcare segment. It has expanded its product portfolio from antibiotics to general remedies. The company has posted average growth for the reported periods. Based on its recent financial data, the issue appears fully priced. Well-informed/cash surplus investors may park moderate funds for medium term. Read detail review...
Jfl Life Sciences Rights Issue 2026 got subscribed by 0.01 times by the end of the bidding period with total bid quantity received by NSE of 1,98,000 shares. Check Day by Day Subscription Details (Live Status)
| Date | NSE Bid Quantity | Subscription Times |
|---|---|---|
Mar 24 2026 17:00:06 | 1,98,000 | 0.01x |
Jfl Life Sciences Limited
309, Satyam Mall,
Opp. Saman Complex, Nr.Vishweshwar Mahadev Mandir,
Satellite
Ahmedabad, 380015
The Jfl Life Sciences Rights Issue 2026 opens on Mon, Mar 16, 2026, and closes on Tue, Mar 24, 2026.
Jfl Life Sciences Rights Issue 2026 Schedule
| Last Date for credit of Rights Entitlements | Fri, Mar 13, 2026 |
| Last Date for renunciation of Rights Entitlements | Thu, Mar 19, 2026 |
| Issue Opening Date | Mon, Mar 16, 2026 |
| Issue Closing Date | Tue, Mar 24, 2026 |
| Date of Allotment (on or about) | Mon, Mar 30, 2026 |
| Date of Credit (on or about) | Thu, Apr 2, 2026 |
| Date of Listing (on or about) | Tue, Apr 7, 2026 |
You can apply for Jfl Life Sciences Rights Issue 2026 in two ways:
Steps to apply for Jfl Life Sciences Rights Issue 2026 using Net Banking (ASBA)
Steps to apply for Jfl Life Sciences Rights Issue 2026 using Registrar's website (R-WAP)
